Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides

Area of Science:

• Pharmacology
• Drug Development
• Biochemistry

Background:

• Phosphorothioate (PS) oligodeoxynucleotides are the most advanced antisense drugs in clinical development.
• Antisense oligonucleotide technology faces challenges in therapeutic drug development, particularly regarding in vivo pharmacokinetics.

Purpose of the Study:

• To investigate the pharmacokinetic behavior of PS oligodeoxynucleotides in vivo.
• To understand the factors influencing the distribution and elimination of these antisense compounds.

Main Methods:

• Pharmacokinetic studies were conducted on PS oligodeoxynucleotides.
• Analysis of absorption from parenteral sites, tissue distribution, blood-brain barrier penetration, and elimination pathways.

Main Results:

• PS oligodeoxynucleotides show good absorption from parenteral administration sites.
• These compounds distribute widely to peripheral tissues but do not cross the blood-brain barrier.
• Elimination occurs primarily through slow metabolism within tissues.

Conclusions:

• The pharmacokinetic properties of PS oligodeoxynucleotides are predominantly influenced by their chemical composition.
• Sequence does not appear to be a major driver of their in vivo behavior.